anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To obtain a skin cosmetic having light burden to skin and excellent massaging effect in rubbing into skin, high moisture retention effect and excellent handleability, comprising salt as a main component, by using both hyaluronic acid or its salt and a supernatant liquid of culture of lactic acid bacteria. CONSTITUTION: This skin cosmetic is obtained by combining salt with hyaluronic acid or its salt and a supernatant liquid of culture of lactic acid bacteria. More excellent moisture retention effect and a feeling in use are obtained by using powdered salt having 10-1,000μm, especially 50-500μm average particle diameter as the salt. For example, hyaluronic acid or its salt derived from an animal such as one extracted from a crest of a chicken or a product by a microorganism may be used as the hyaluronic acid or its salt. The hyaluronic acid or its salt having 400,000 to 3,000,000 molecular weight is preferably used. The amount of the hyaluronic acid or its salt added is 0.001-5%, especially 0.001-3% based on the salt. The amount of the supernatant liquid of lactic acid bacteria is 0.01-20%, especially 0.01-10% based on the salt.  The skin cosmetic is usable with ease without damaging skin by action of hyaluronic acid. The skin cosmetic will not drop from a hand in rubbing it into skin.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention refers to medicine, particularly to pharmaceutical industry, and concerns a drug in the form of a gel for treating mycoses of various localisations: inguinal dermatophytosis, mucocutaneous candidiasis, foot dermatophytosis, balanoposthitis, trophic ulcers, and other diseases complicated by mycotic or microbial flora. The agent contains an active substance, auxiliary substances and a base where as the active substance, it contains a mixture of alpha-, or beta-, or gamma recombinant interferon in amount 100-5000000 IU/g, terbinafine hydrochloride and metronidazole in proportions 1:1-5. The agent also can contain the others antiviral, antimicrobial, anti-inflammatory, immunomodulating and bactericidal substances. ^ EFFECT: invention provides diseased tissue repair without colloidal cicatrisation and promotes reduced length of treatment. ^ 7 cl, 6 ex
Depression and anxiety are among the most frequently diagnosed psychological disorders, with persistent patterns of impairment evident from childhood through adulthood. Impaired functioning of core brain systems that respond to reward and errors may increase risk for depression and anxiety. Importantly, these neural risk markers for depression and anxiety appear to be shaped, at least in part, by environmental input. Problematic parenting is a key environmental factor involved in the intergenerational transmission of depression and anxiety. Low positive parenting is associated with blunted brain responses to reward and harsh parenting is associated with heightened brain responses to errors. This study uses an evidence-based parenting program to test causal links between dimensions of positive and harsh parenting and children's brain responses to rewards and errors. Participants will include 80 6- to 7-year-old children and their mothers who will be randomly assigned to participate in a parenting program (Parent Child Interaction Therapy: PCIT) or to a waitlist control group, and brain responses to rewards and errors will be assessed pre- and post-intervention.
1346535 Diphenylamines L'OREAL 13 July 1972 [14 July 1971] 32815/72 Heading C4P [Also in Division D1] The invention comprises diphenylamines of the general formula wherein each of R 1  and R 2  are H 1  halogen of C 1 -C 4  alkyl, at least one of R 1  and R 2  being other than H, each of R 3 , R 4 , R 5 , R 6  and R 7  is H or C 1 -C 4  alkyl optionally substituted by one or more OH, carbamoyl, piperidinyl or acylamino groups, or R 3  and R 6  or R 4  and R 7  together with the linking carbon and nitrogen atoms complete dihydrooxazinyl or pyrrolinyl rings, and 2 is an amino, acylamino or OH group, and their salts with organic and inorganic acids, e.g. hydrochlorides, oxalates and tartrates. They are prepared by (a) reducing the corresponding indoaniline in an aqueous alkaline medium with a reducing agent, e.g. sodium hydrosulphite or ammonium sulphide or in an organic solvent, e.g. an alcohol by catalytic hydrogenation using palladium or barium sulphate or on charcoal or (b) by condensing a dinitro compound of general formula with a p-aminophenol substituted by R 1  and R 2  and then reducing the dinitro diphenylamine formed. The dyes are used to dye hair.
Patients will have a "Bivalve Split Cast" long arm cast applied after they have undergone a closed reduction of of forearm fractures. This is a cast that will be split on both sides of the cast. 20 patients will be randomized to the bivalve split arm cast.
This trial assessed the efficacy of naproxen in patients with sciatica in outpatient clinics across 4 Norwegian hospitals. A total of 123 adults with radiating pain below the knee (≥4 on a 0-10 numeric rating scale) and signs consistent with nerve root involvement were included. Participants were randomized to receive either naproxen 500 mg or a placebo twice daily for 10 days. The primary outcome, daily leg pain intensity measured on a 0 to 10 numeric rating scale throughout the treatment period, revealed a statistically significant difference in favor of naproxen, with an adjusted mean difference of -0.5 (95% CI -0.8 to -0.1, P = 0.015). In the naproxen group, the treatment effect was significantly related to time, and over the whole 10-day period, the average adjusted difference was -0.6 (95% CI -0.8 to -0.5). Mean numbers needed to treat for 30% and 50% improvement were 9.9 (95% CI 4.7-15.0) and 20.7 (8.7-32.7), respectively. The adjusted mean difference for back pain was -0.4 (95% CI -0.8 to 0.0), and for Roland Morris Disability Questionnaire for Sciatica, it was -1.5 (95% CI -3.0 to 0.0). No differences were found for sciatica bothersomeness or consumption of rescue medication or opioids. Participants in the naproxen group exhibited an adjusted odds ratio of 4.7 (95% CI 1.3-16.2) for improvement by 1 level on the global perceived change scale. In conclusion, naproxen treatment showed small, likely clinically unimportant benefits compared with placebo in patients with moderate-to-severe sciatica.
This study has two components. First, there will be a 60 minute online session. During this session, participants will first be asked to complete the informed consent process, a demographics and contact form, a series of questionnaires, a working memory assessment, and a HIPAA authorization. Researchers will also conduct a brief interview about the participant's medical history (including questions about mood, personality, and symptoms of borderline personality disorder), which is used to assess eligibility for participation in the study.

If eligible to continue, participants will complete one 90 minute in-person experiment session. During the in-person session, participants will be randomly assigned (like flipping a coin) to ingest either a placebo (non-active) or the combination of hydrocortisone and yohimbine. Ingesting hydrocortisone and yohimbine will increase participants' neuroendocrine (hormone) levels, which naturally become elevated in response to stress. After ingesting either the placebo or hydrocortisone plus yohimbine, participants will complete a series of questionnaires on a computer as well as an online decision-making task. While completing the computer task, participants' heart rate and pupil size activity will be monitored using an ECG monitor and an eye tracker. Three salivary samples will also be collected during this session: one immediately before participants ingest the placebo or hydrocortisone/yohimbine combination and two immediately before and after participants complete the computer game. These salivary samples will be collected, stored, then assayed, a process that allows us to measure participants' cortisol levels, a hormone important for the body's stress response.
FIELD: medicine, oncology. SUBSTANCE: 250 ml of peripheral venous autoblood is taken off and 150 ml of autoblood is incubated with antitumor chemopreparations. The remained 100 ml of blood are incubated with Intron-A taken in the dose 15 x 10 IU. Both mixtures taken in separated flasks are placed into thermostat at 37 C for 1 h. Then the blood mixture containing antitumor chemopreparations is infused by drop route for 25-30 min and blood mixture with Intron-A is infused for 2-3 h. Procedure is repeated on 8-th day. The total treatment course is 6. Method ensures to provide effective tumor cells killing in circulating blood and damaged foci, to decrease tumor size and lymph nodes, to decrease toxicity of administrated preparations, to stimulate immunoreactivity and total nonspecific immunological resistance of body. Invention can be used in treatment of patients with non-Hodgkin's lymphomas of II-IV stages of disease. EFFECT: enhanced effectiveness of treatment. 2 ex
Racism is associated with negative intergenerational (infant) outcomes. That is, racism, both perceived and structural, is linked to critical, immediate, and long-term health factors such as low birth weight and infant mortality. Antiracism-resistance to racism such as support for the Black Lives Matter (BLM) movement-has been linked to positive emotional, subjective, and mental health outcomes among adults and adolescents. To theoretically build on and integrate such past findings, the present research asked whether such advantageous health correlations might extend intergenerationally to infant outcomes? It examined a theoretical/correlational process model in which mental and physical health indicators might be indirectly related to associations between antiracism and infant health outcomes. Analyses assessed county-level data that measured BLM support (indexed as volume of BLM marches) and infant outcomes from 2014 to 2020. As predicted, in the tested model, BLM support was negatively correlated with 1) low birth weight (Ncounties = 1,445) and 2) mortalities (Ncounties = 409) among African American infants. Given salient, intergroup, policy debates tied to antiracism, the present research also examined associations among White Americans. In the tested model, BLM marches were not meaningfully related to rates of low birth weight among White American infants (Ncounties = 2,930). However, BLM support was negatively related to mortalities among White American infants (Ncounties = 862). Analyses controlled for structural indicators of income inequality, implicit/explicit bias, voting behavior, prior low birth weight/infant mortality rates, and demographic characteristics. Theory/applied implications of antiracism being linked to nonnegative and positive infant health associations tied to both marginalized and dominant social groups are discussed.
Methods for removing endotoxin from naturally occurring materials, such as polysaccharides (e.g., agarose and/or carrageenan) are described herein. Polysaccharides that are substantially free of endotoxins and uses thereof are also described. The polysaccharide materials can be isolated from microorganisms, multicellular organisms, such as, algae, plants, seaweed, etc. The method involves the use of acidic and basic solutions to hydrolyze the lipid-polysaccharide bond in endotoxins. Cleaving the fatty acid from the polysaccharide reduces the water-solubility of the fatty acid and enables its removal with an organic solvent such as ethanol. The polysaccharide component can also undergo acidic or basic hydrolysis due to the weak glycosidic bond between the sugar rings.
Participants will receive 0.9% normal saline in the OR. The amount received will be equivalent of what would be given if they were receiving IV acetaminophen.
The primary goal of osteoporosis therapy is to prevent fracture, and anabolic agents can accomplish this by strengthening bone structure, which is accompanied by changes in BMD. Effects of ALX1-11 on BMD have been previously documented in a dose-finding Phase II clinical trial in osteoporotic postmenopausal women taking calcium and vitamin D supplements, who were otherwise naive to osteoporosis therapies. The anabolic effects of ALX1-11 on lumbar vertebrae were statistically significant compared to placebo after 12 months of treatment. In addition, animal studies showed that the new bone formed by treatment with ALX1 11 is of good quality both histologically and biomechanically (Mosekilde et al., 1991; Kimmel et al., 1993).

Protocol ALX1-11-93001 (TOP) assessed the effect of 18 months of ALX1-11 treatment on fracture incidence as a primary efficacy variable, and Protocol CL1-11-002 (OLES) assessed the effect on BMD for up to 24 months of treatment. Subjects who will be enrolled in the current study (TRES) will be those who received placebo in TOP and ALX1-11 in OLES. TRES will evaluate the effects of continued ALX1-11 treatment on the safety and efficacy variables assessed in the OLE study for a maximum treatment duration of 36 months in the OLES and TRES combined.
The participants allocated to the control condition will be put on a waiting list and offered the CBT-CSO program after 10 weeks. The CSOs will receive information about available treatment options-in their area and web-based-for the problem gambler.
OBJECTIVE: To test the hypothesis that moxibustion may inhibit rheumatoid arthritis (RA) synovial inflammation by regulating the expression of macrophage migration inhibitory factor (MIF)/glucocorticoids (GCs).
METHODS: Fifty male Sprague-Dawley rats were randomly divided into five groups (n = 10 each): blank Control (CON) group, RA Model (RA) group, Moxibustion (MOX) group, MIF inhibitor (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester (ISO-1) group, and Moxibustion + MIF inhibitor ISO-1 (MOX + ISO-1) group. Rats in the ISO-1 group and ISO-1 + MOX group were intraperitoneally injected with the inhibitor ISO-1. The rats in the RA group, ISO-1 group, MOX group, and ISO-1 + MOX group were injected with Freund's complete adjuvant (FCA) in the right hind footpad to establish an experimental RA rat model. In the MOX group and MOX + ISO-1 group, rats were treated with Moxa. The thickness of the footpads of the rats in each group was measured at three-time points before, after modeling and after moxibustion treatment. The contents of serum MIF, corticosterone (CORT), tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) were detected by enzyme-linked immunosorbent assay; and the contents of synovial MIF were detected by Western blot. Hematoxylin-eosin (HE) staining method was used to observe the pathological changes of synovial tissue under a section light microscope, and pathological scoring was performed according to the grading standard of the degree of synovial tissue disease.
RESULTS: Moxibustion was found to reduce the level of MIF and alleviate inflammation in RA rats in this study. In addition, after inhibiting the expression of MIF, the level of CORT increased, and the level of TNF-α decreased. Treating RA rats with inhibited MIF by moxibustion, the level of CORT was almost unchanged, but the level of TNF-α further decreased. The correlation analysis data suggested that MIF was positively related to the expression of TNF-α and negatively correlated with the expression of CORT.
CONCLUSION: Reducing MIF to increase CORT and decrease TNF-α by moxibustion treatment in RA. MIF may be a factor for moxibustion to regulate the expression of CORT, but the expression of TNF-α is due to the incomplete regulation of the MIF. This study added to the body of evidence pointing to moxibustion's anti-inflammatory mechanism in the treatment of RA.
PURPOSE: A composition containing acidic electrolyzed water with anti-influenza virus activity is provided to enable long-term administration without side effects and toxicity. CONSTITUTION: A composition with an anti-influenza virus activity contains acidic electrolyzed water. The influenza virus is influenza virus type A, B, or C. The influenza virus is H1N1 influenza virus, A/PR/8/34(H1N1). The ORP(oxidation-reduction potential) of the acidic electrolyzed water is 400-1200 mV. A pharmaceutical composition for preventing or treating influenza viral disease contains the composition as an active ingredient. A food composition for preventing or treating influenza viral diseases contains acidic electrolyzed water as an active ingredient.
An oral medication delivery system and method for pharmaceutically active agents having local and/or systemic effect is provided. The system provides three embodiments of containers in which medication is stably stored, either in liquid suspension or in dry powder form with a delivery liquid, until dispensed for use by a patient. The medication is mixed as required and frozen in the storage container until hard, when it is administered to the patient in the form of a frozen popsicle. One embodiment of the system includes a flexible plastic container which contains the pharmaceutically active agent mixed with a delivery liquid. In other embodiments the medication in powder form and a delivery liquid are stored in a chambered container separated by a rupturable membrane which is ruptured to mix the container contents prior to freezing. The oral medication delivery system of the present invention is particularly well suited for delivering Nystatin to oral candidiasis lesions, particularly to the very young, the elderly and those unable to take medications by traditional administration methods.
PROBLEM TO BE SOLVED: To provide electrochemically bioactive fine particles capable of giving a field abundant in anions to vital tissue when orally ingested. SOLUTION: The electrochemically bioactive fine particles supply negative electric charges to the inside of the vital bodies of animals and plants so as to develop electrochemical bioactivation. The electrochemically bioactive fine particles preferably comprise fine particles of a noble metal, such as gold, platinum and palladium, and more preferably comprise colloidal platinum particles. The colloidal platinum particles each have a size of 2-3 nm as a single particle and are dispersed in such a state that the single particles aggregate to form chain-shaped particles having a size of 4-8 nm. The platinum colloid comprising the colloidal platinum particles forms the field abundant in anions inside the vital bodies and continuously gives electric potential to water molecules absorbed through gastrointestinal membrane.  These characteristics are maintained while the platinum colloid is orally ingested, then passed through the large bowel and finally discharged from the fundament. Further, the platinum colloid does not stay inside the vital bodies.
On top of the usual care, subjects in the intervention will receive a lifestyle intervention that will be delivered by experienced registered dietitian and exercise specialist. There will be 5 face-to-face dietitian consultations, 2 telephone dietitian consultations and at least one face-to-face exercise specialist consultation. The exercise consultation will be normally scheduled on the same day of the face-to-face dietitian consultation.
* Instruct patients to apply immediately after removal from the individually sealed pouch.  
Instruct patients not to use buprenorphine transdermal system if the pouch seal is broken or the patch is cut, damaged, or changed in any way. See the Instructions for Use for step-by-step instructions for applying buprenorphine transdermal system.
  * Apply buprenorphine transdermal system to the upper outer arm, upper chest, upper back or the side of the chest. These 4 sites (each present on both sides of the body) provide 8 possible application sites. Rotate buprenorphine transdermal system among the 8 described skin sites. After buprenorphine transdermal system removal, wait a minimum of 21 days before reapplying to the same skin site [see Clinical Pharmacology (12.3)].
  * Apply buprenorphine transdermal system to a hairless or nearly hairless skin site. If none are available, the hair at the site should be clipped, not shaven. Do not apply buprenorphine transdermal system to irritated skin. If the application site must be cleaned, clean the site with water only. Do not use soaps, alcohol, oils, lotions, or abrasive devices. Allow the skin to dry before applying buprenorphine transdermal system.
  * Incidental exposure of the buprenorphine transdermal system patch to water, such as while bathing or showering is acceptable based on experience during clinical studies.
  * If problems with adhesion of buprenorphine transdermal system occur, the edges may be taped with first aid tape. If problems with lack of adhesion continue, the patch may be covered with waterproof or semipermeable adhesive dressings suitable for 7 days of wear.
  * If buprenorphine transdermal system falls off during the 7-day dosing interval, dispose of the transdermal system properly and place a new buprenorphine transdermal system patch on at a different skin site.
  * When changing the system, instruct patients to remove buprenorphine transdermal system and dispose of it properly [see Dosage and Administration (2.8)].
  * If the buprenorphine-containing adhesive matrix accidentally contacts the skin, instruct patients or caregivers to wash the area with water and not to use soap, alcohol, or other solvents to remove the adhesive because they may enhance the absorption of the drug.
Both plants of the patient's feet will be observed by a thermal camera. Static observations (taking a single image), or dynamic (taking a series of images) of the foot, will be made. In the latter case, the observation will be done after a brisk walk of 6 min. The instruction given to patients will be to go the furthest in 3 min and then come back in 3 min, all while walking. The observation will be made by cameras without contact. These thermal cameras are non-invasive and non-ionizing, there is no risk related to their use. The camera will be placed on a tripod, a few tens of centimeters from the foot, and connected to a laptop (for the images acquisition). A wooden box, painted black, will be placed around both feet to protect the scene from parasitic thermal radiation that can disturb temperature variations. Foam will protect the skin / wood interface. Electric resistances, fixed on the box, will be placed in the field of vision of the thermal camera to guarantee the good treatment of the images. These resistors will never be in contact with the patient. The area filmed by the camera will be limited to the sole arch and, sometimes, the hand of patients to see if a thermal anomaly is also present on this member.